In this analysis of HER2-negative aBC patients treated with the first chemotherapy in the advanced setting, we evaluated frequencies of germline mutations in BC risk genes and showed that 4.9% of patients had a BRCA1/2m and about 1.5% of patients had a PALB2 mutation. This evidence concerns the gene ERBB2 and breast cancer.